Intralesional epidermal growth factor treatment on diabetic foot ulcers: one centre experience

Introduction: The intralesional injection of recombinant human epidermal growth factor (EGF-IL) is a new approach for reducing amputations. In this study we aimed to show efficacy of EGF-IL with cases. Material and Method: EGF-IL 75 μg application to 8 diabetic foot ulcers (6 males, 2 females; mean age: 60.3±9.3 years) was evaluated. Patients had history of prior standard treatments. Results: All eight patients’ wound healed completely. Conclusion: In our experience on patients wounds wish priorly have healing problems, improved with intralesional EGF. This treatment is expensive and caused of some allergic reactions. Relation with malignancies are not known for long-term.